Blood cancer, typically categorized as leukemia, lymphoma, or myeloma, is a disease in which blood cells grow too much or develop abnormally.| Rare Cancer News
Category archive page for Myeloma.| Rare Cancer News
Treatment for gliomas can involve surgery, radiation therapy, and chemotherapy, as well as a range of supportive treatments.| Rare Cancer News
Pediatric low-grade gliomas are generally softer than normal brain tissue, a first-of-its-kind study reports.| Rare Cancer News
Marisa Wexler is a senior science writer for Myeloma Research News with an MS in cellular and molecular pathology. She covers the latest news and information on a variety of myeloma topics.| Rare Cancer News
The oral liquid can treat specific forms of acute lymphoblastic leukemia and chronic myeloid leukemia, and other cancers, including rare ones.| Rare Cancer News
*** Myeloma Research News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician...| Rare Cancer News
Revlimid (lenalidomide) is an immunomodulatory anti-cancer treatment developed by Celgene for multiple myeloma and other diseases.| Rare Cancer News
Pomalyst (pomalidomide) is an oral treatment for multiple myeloma patients whose disease has relapsed or is not responsive to other treatments.| Rare Cancer News
Learn about Darzalex (daratumumab), an antibody therapy approved by the FDA alone or in combination to treat various groups of multiple myeloma patients.| Rare Cancer News
Patricia Inacio is a science writer for Myeloma Research News with a PhD in cell biology. She covers the latest news and information on a variety of myeloma topics.| Rare Cancer News
Kite Pharma has initiated a global Phase 3 trial to test the CAR T-cell therapy anito-cel in relapsed or refractory multiple myeloma.| Rare Cancer News
Margarida Maia is a science writer for Myeloma Research News with a PhD in biomedical sciences. She covers the latest news and information on a variety of myeloma topics.| Rare Cancer News
Lindsey Shapiro is a science writer for Myeloma Research News with a PhD in neuroscience. She covers the latest news and information on a variety of myeloma topics.| Rare Cancer News
The FDA has agreed to review GSK’s request to approve Blenrep as a second-line combination treatment for multiple myeloma.| Rare Cancer News
AbbVie’s Elahere has been approved in the European Union as a treatment for adults with advanced, platinum-resistant ovarian cancer.| Rare Cancer News
Phase 3 trial in nearly 500 advanced disease patients found combination therapy using Blenrep more effective at extending life than Darzalex.| Rare Cancer News
Steve Bryson is a science writer for Myeloma Research News with a PhD in biochemistry. He covers the latest news and information on a variety of myeloma topics.| Rare Cancer News
Based on a clinical trial, the CAR T-cell therapy was approved for relapsed or refractory precursor B-cell acute lymphoblastic leukemia.| Rare Cancer News
A new case report describes the challenging diagnosis of a teenage girl with a rare pancreatic neuroendocrine tumor that spread to the liver.| Rare Cancer News
Ovarian cancer tumors' microenvironment was seen to actively suppress the anti-cancer work of immune T-cells by blocking their energy supply.| Rare Cancer News
About 15% relapsed in the first year and patients lived a median of 7.5 years, and without disease progression for a median of three years.| Rare Cancer News
The FDA granted regenerative medicine advanced therapy status to the CAR T-cell therapy P-BCMA-ALLO1 for hard-to-treat multiple myeloma.| Rare Cancer News